Abstract
Introduction: The use of systemic corticosteroids (SCS), including oral corticosteroids (OCS) is a common therapeutic option in acute asthma and its maintenance management. RAPID (NCT04287621) is a global, prospective registry that aims to characterize patients with asthma initiating dupilumab in real-world clinical practice.
Objective: To report baseline characteristics with focus on SCS use in patients enrolled in RAPID.
Methods: RAPID is enrolling patients aged ≥12 years who initiate dupilumab for asthma (primary indication) according to country-specific prescribing information.
Results: Between Mar 6, 2020 and Oct 28, 2021, 205 patients were enrolled. 54/205 pts (26%) had received SCS in the 3 months prior. OCS treatment was ongoing for 25 patients (48%). All patients were on maintenance inhaled corticosteroids (ICS) (Table). Moreover, 13/16 (81%) patients with baseline blood eosinophil counts available had counts of ≥ 150 cells/mL and 17/22 (77%) patients with baseline fractional exhaled nitric oxide (FeNO) available had FeNO ≥ 25 ppb. Other baseline characteristics and inflammatory biomarkers are shown (Table).
Conclusions: In this initial presentation of baseline characteristics of patients from RAPID initiating dupilumab for moderate-to-severe asthma, we show that ≥ 25% of patients were currently or had recently received SCS, indicating a high unmet need in this population.
Footnotes
Cite this article as: European Respiratory Journal 2023; 62: Suppl. 67, PA5290.
This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2023
